Dose-dense neoadjuvant chemotherapy in triple-negative breast cancer: Real-world data from a developing country.
Rakesh Kumar SharmaAjay GogiaSuryanarayana S V DeoDaya Nand SharmaSandeep R MathurHari Krishna Raju SagirajuPublished in: Indian journal of cancer (2024)
This observational study focusing on ddNACT among TNBC patients demonstrated significant differences in the relapse rate with no survival benefits. Differential effects of ddNACT by tumor presentation (early vs. late), tumor size, tumor biology, and cost-benefits of granulocyte colony-stimulating factor support with such regimens need further exploration.
Keyphrases
- neoadjuvant chemotherapy
- end stage renal disease
- locally advanced
- chronic kidney disease
- ejection fraction
- lymph node
- newly diagnosed
- free survival
- squamous cell carcinoma
- peritoneal dialysis
- prognostic factors
- peripheral blood
- patient reported outcomes
- machine learning
- rectal cancer
- radiation therapy
- case report
- artificial intelligence
- patient reported